Johns Hopkins psychedelics researcher Matthew Johnson on how psilocybin, DMT, and addiction science reveal the mind's hidden flexibility and depth.

Matthew Johnson: A professor of psychiatry and behavioral sciences at Johns Hopkins and one of the world's leading scientists studying psychedelics, addiction, and behavioral economics.
Matthew Johnson gives a wide-ranging tour of psychedelics, distinguishing classic compounds (psilocybin, LSD, DMT, mescaline) from MDMA and others by their pharmacology, safety, and subjective effects. He explains his behavioral-economics lens on addiction (demand curves, elasticity, delay discounting) and applies it to drug policy, sexual decision-making, and his celebrated psilocybin smoking-cessation trials. He details how high-dose sessions are run at Hopkins with the mantra 'trust, let go, be open.' The conversation widens into consciousness, panpsychism, Elon Musk's first-principles thinking, Neuralink, aliens, and ultimately death and the meaning of life.
Kary Mullis
“he says he wouldn't have won the nobel prize from it said he wouldn't have come up with that had he not had psychedelic experiences um you know now he's an interesting character people should read his autobiography”— guest
Robert Masters and Jean Houston
“masters in houston that wrote a really good book the varieties of psychedelic experience kind of which is a play on varieties of religious experience by william james”— guest
William James
“the varieties of psychedelic experience kind of which is a play on varieties of religious experience by william james”— guest
Cal Newport
“cal newport if you know who that is um he wrote a book called deep work he's a computer science professor and he's currently working on a book about email”— guest
Aldous Huxley
“like huxley aldous huxley with his mescaline experience and doors of procession like there's an is-ness there”— guest
Emergent BioSolutions
“naloxone which is an antagonist it goes into the receptor it's called narcan that's the trade name but it's what they revive people on an opioid overdose”— guest